Andrew Holden: Nellix EVAS Global Forward Registry



Andrew Holden (Auckland City Hospital, Auckland, New Zealand) is one of the principal investigators of the Nellix EVAS FORWARD Global Registry. He explained to Vascular News what to consider when selecting abdominal aortic aneurysm patients for Nellix treatment, why the instructions for use are so important and its performance in other applications such as ruptured aneurysms, juxtarenal aneurysms, and for repair of failed EVAR.